• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Derm Rare Disease Openings

Quote
































Respiratory reps will likely go for the roles, but it will be a difficult sell for them. Hell, they can barely sell Spiriva. How do they expect to see in ultra rare space with reimbursement obstacles.
 




anonymous said:
Respiratory reps will likely go for the roles, but it will be a difficult sell for them. Hell, they can barely sell Spiriva. How do they expect to see in ultra rare space with reimbursement obstacles.
Click to expand...
BI Respiratory reps have not had to learn anything new in years. I do no not know any that would qualify, unless using a miniature doll as visual aid is part of the job description.
 




anonymous said:
BI Respiratory reps have not had to learn anything new in years. I do no not know any that would qualify, unless using a miniature doll as visual aid is part of the job description.
Click to expand...

All our resp reps are old and worn out. we don’t have any attractive reps anymore so that other ‘tactic’ is not gonna work either.
 




































Why would anyone want an ultra rare disease role at BI where you can’t get stock options, when every other rare disease company throws $100k in options at reps on the day of signing?
 




Top Bottom
Back
Quote